After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Russian scientists have created a microfluidic platform that replicates blood flow in the brain. It is capable of supporting ...

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation.

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

Temozolomide, Radiation Shrink Tumor, Aid Hearing Niigata University Niigata, Japan – A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has ...

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation. The case ...

A group at Niigata University succeeded in the treatment of a brainstem glioma patient with a rare IDH2 mutation. Brainstem gliomas with H3K27M mutation are usually refractory to temozolomide ...

Recommendations focus on radiation therapy and/or adjunctive therapies for WHO grade 4 adult-type diffuse glioma.